Protego Biopharma Appoints Jae Kim as Chief Medical Officer
Protego Biopharma has named Jae Kim as its new chief medical officer (CMO), according to a company announcement released June 19, 2026. Kim, who previously served in similar roles at Septerna and Design Therapeutics, will oversee the biopharmaceutical firm’s clinical development strategies and regulatory affairs, according to a press release.
Background on Jae Kim’s Career
Kim’s professional trajectory includes leadership positions at Septerna, a biotechnology company focused on oncology, and Design Therapeutics, which specializes in RNA-targeted therapies. While specific details about his tenure at these firms were not immediately available through independent verification, industry analysts note that his appointment reflects Protego’s strategy to strengthen its clinical pipeline.
Protego Biopharma’s Strategic Focus
The Chicago-based biopharmaceutical company has been advancing therapies for rare genetic disorders, with a pipeline including investigational treatments for lysosomal storage diseases. The hiring of Kim follows a series of executive changes at Protego, including the 2025 appointment of a new chief business officer. A spokesperson for the company stated that Kim’s expertise in navigating regulatory pathways will be critical as Protego prepares to advance multiple drug candidates into late-stage trials.
Implications for the Biotech Sector
Kim’s move to Protego aligns with broader trends in the biotechnology industry, where firms are increasingly prioritizing experienced clinical leaders to accelerate drug development. According to a 2026 report by Evaluate Pharma, 68% of biotech companies cited leadership expertise as a key factor in successful regulatory approvals. Kim’s background in RNA-based therapies may also position Protego to capitalize on growing interest in gene-targeted treatments.
What’s Next for Protego Biopharma?
The company has not yet disclosed specific timelines for upcoming trials but indicated in its press release that Kim will play a central role in shaping its 2027 development roadmap. Investors are closely watching the firm’s progress, as its lead candidate, PBT-101, is set to enter Phase III trials later this year.
Continue to STAT+ for the full story.
Keep reading